Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Indemnity Calculus For Covid-19 Vaccines, India’s Path Ahead

Executive Summary

Legal experts discuss the intricacies around pharma’s demand for indemnity, a key sticking point for supplies of COVID-19 vaccines from Pfizer and Moderna, and the path forward for countries like India.

You may also be interested in...



World No. 1 Or US No. 3? Global Access May Factor Into US Booster Shot Decision

A third shot of COVID-19 vaccine may be recommended for Americans soon, but the CDC says the best defense against the pandemic in the US includes ensuring the entire world gets the primary series.

COVID-19 Vaccine Safety Now: Soft Rollout, Not Pause, After Reports Of Guillain-Barré Syndrome

Unlike its response to incidents of blood clots with J&J’s vaccine, the US FDA is not calling for a pause in its administration following reports of about 100 cases of Guillain-Barré syndrome. CDC advisory panel is to discuss the issue at an upcoming meeting.

With J&J’s COVID Vaccine Pause Now Lifted, The Question Is How Well The System Worked

Number of deaths and ICU admissions that may have been prevented without the pause is ‘striking,’ CDC advisory committee member says; ACIP votes to reaffirm use of J&J’s vaccine in persons 18 and older based on positive risk-benefit analysis and reports of only nine additional cases of TTS.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel